What is ERA?

The Endometrial Receptivity Assay (ERA) is a personalized diagnostic test that assesses the endometrium’s ability to receive an embryo.

It determines the optimal time for embryo transfer by analyzing the genetic expression in the endometrial lining. An ERA is helpful for women experiencing implantation failure or those with repeated IVF failures.

Eligibility for ERA:

Despite good-quality embryos, women with multiple IVF failures are ideal candidates for ERA.

Similarly, if a woman has a short menstrual cycle or unusual hormonal patterns, it may indicate endometrial receptivity issues, and the ERA can provide valuable insights.

The Process:

The ERA procedure involves two steps:

1. Step 1: Endometrial Sampling
   Endometrial sampling is performed either during the previous cycle or on the same day a fertility cycle starts. The physician uses a small suction device to obtain a sample of the patient’s endometrial tissue.
2. Step 2: Transcriptomic Analysis
   The endometrial sample is analyzed in the laboratory. The expression of specific genes is studied, which helps determine the endometrium’s receptive status. The data obtained from the analysis is then used to develop a personalized embryo transfer plan.

Benefits of Endometrial Receptivity Assay:

The Endometrial Receptivity Assay has numerous benefits, including:

1. Personalized Treatment:
   The test enables physicians to develop a personalized embryo transfer plan that works best for the patient, leading to higher success rates.
2. Fewer Implantation Failures:
   The ERA ensures that the endometrium is adequately receptive, reducing the chances of repeated implantation failures.
3. Better Timing of Embryo Transfer:
   The test helps determine the ideal timing for embryo transfer, improving the chances of successful conception.